New registry tracks PRRT outcomes for neuroendocrine cancer patients
NCT ID NCT04090034
First seen Mar 22, 2026 · Last updated Jun 19, 2026 · Updated 17 times
Summary
This study is tracking 50 adults with neuroendocrine tumors who are receiving peptide receptor radionuclide therapy (PRRT). Researchers are collecting data on patient characteristics, treatment responses, survival, and side effects. The goal is to better understand who benefits from PRRT and how the therapy affects the disease over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Research Institute at Methodist Health System
RECRUITINGDallas, Texas, 75203, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Methodist Dallas Medical Center
ENROLLING_BY_INVITATIONDallas, Texas, 75203, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Peptide receptor radionuclide therapy (PRRT)
What this could lead to
If successful, this could help doctors better understand which patients benefit most from PRRT and improve treatment decisions for neuroendocrine tumors.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove PRRT works. Results may be limited by small size and lack of a comparison group.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.